Overnight switch from ropinirole to transdermal rotigotine patch in patients with Parkinson disease

Han-Joon Kim, Beom S Jeon, Won Yong Lee, Myoung Chong Lee, Jae Woo Kim, Jong-Min Kim, Tae-Beom Ahn, Jinwhan Cho, Sun Ju Chung, Frank Grieger, John Whitesides, Babak Boroojerdi, Han-Joon Kim, Beom S Jeon, Won Yong Lee, Myoung Chong Lee, Jae Woo Kim, Jong-Min Kim, Tae-Beom Ahn, Jinwhan Cho, Sun Ju Chung, Frank Grieger, John Whitesides, Babak Boroojerdi

Abstract

Background: A recent trial involving predominantly Caucasian subjects with Parkinson Disease (PD) showed switching overnight from an oral dopaminergic agonist to the rotigotine patch was well tolerated without loss of efficacy. However, no such data have been generated for Korean patients.

Methods: This open-label multicenter trial investigated PD patients whose symptoms were not satisfactorily controlled by ropinirole, at a total daily dose of 3 mg to 12 mg, taken as monotherapy or as an adjunct to levodopa. Switching treatment from oral ropinirole to transdermal rotigotine was carried out overnight, with a dosage ratio of 1.5:1. After a 28-day treatment period, the safety and tolerability of switching was evaluated. Due to the exploratory nature of this trial, the effects of rotigotine on motor and nonmotor symptoms of PD were analyzed in a descriptive manner.

Results: Of the 116 subjects who received at least one treatment, 99 (85%) completed the 28-day trial period. Dose adjustments were required for 11 subjects who completed the treatment period. A total of 76 treatment-emergent adverse events (AEs) occurred in 45 subjects. No subject experienced a serious AE. Thirteen subjects discontinued rotigotine prematurely due to AEs. Efficacy results suggested improvements in both motor and nonmotor symptoms and quality of life after switching. Fifty-two subjects (46%) agreed that they preferred using the patch over oral medications, while 31 (28%) disagreed.

Conclusions: Switching treatment overnight from oral ropinirole to transdermal rotigotine patch, using a dosage ratio of 1.5:1, was well tolerated in Korean patients with no loss of efficacy.

Trial registration: This trial is registered with the ClincalTrails.gov Registry (NCT00593606).

References

    1. Olanow CW, Agid Y, Mizuno Y, Albanese A, Bonucelli U, Damier P. et al.Levodopa in the treatment of Parkinson's disease: Current controversies. Mov Disord. 2004;19:997–1005. doi: 10.1002/mds.20243.
    1. Chase TN. Levodopa therapy: Consequences of the nonphysiologic replacement of dopamine. Neurology. 1998;50(Suppl5):S17–25.
    1. Parkinson Study Group. A randomized controlled trial comparing pramipexole with levodopa in early Parkinson's disease: design and methods of the CALM-PD Study. Clin Neuropharmacol. 2000;23:34–44.
    1. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N Engl J Med. 2000;342:1484–1491. doi: 10.1056/NEJM200005183422004.
    1. Parkinson Study Group. Pramipexole vs Levodopa as Initial Treatment for Parkinson Disease: A 4-Year Randomized Controlled Trial. Arch Neurol. 2004;61:1044–1053.
    1. LeWitt PA, Lyons KE, Pahwa R. on behalf of the SPSG. Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study. Neurology. 2007;68:1262–1267. doi: 10.1212/.
    1. Poewe WH, Rascol O, Quinn N, Tolosa E, Oertel WH, Martignoni E. et al.Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol. 2007;6:513–520. doi: 10.1016/S1474-4422(07)70108-4.
    1. Watts RL, Jankovic J, Waters C, Rajput A, Boroojerdi B, Rao J. Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease. Neurology. 2007;68:272–276. doi: 10.1212/01.wnl.0000252355.79284.22.
    1. LeWitt PA, Boroojerdi B, MacMahon D, Patton J, Jankovic J. Overnight switch from oral dopaminergic agonists to transdermal rotigotine patch in subjects with Parkinson disease. Clin Neuropharmacol. 2007;30:256–265. doi: 10.1097/wnf.0b013e318154c7c4.
    1. Lee JY, Lee EK, Park SS, Lim JY, Kim HJ, Kim JS. et al.Association of DRD3 and GRIN2B with impulse control and related behaviors in Parkinson's disease. Mov Disord. 2009;24:1803–1810. doi: 10.1002/mds.22678.
    1. Giladi N, Boroojerdi B, Korczyn AD, Burn DJ, Clarke CE, Schapira AH. Rotigotine transdermal patch in early Parkinson's disease: a randomized, double-blind, controlled study versus placebo and ropinirole. Mov Disord. 2007;22:2398–2404. doi: 10.1002/mds.21741.
    1. Trenkwalder C, Hoegl B, Kohnen R. et al.The Parkinson's disease sleep scale (PDSS) modified - preliminary results from a validation study. Mov Disord. 2008;23(Suppl1):S356.
    1. Chaudhuri KR, Martinez-Martin P, Brown RG, Sethi K, Stocchi F, Odin P. et al.The metric properties of a novel non-motor symptoms scale for Parkinson's disease: results from an international pilot study. Mov Disord. 2007;22:1901–1911. doi: 10.1002/mds.21596.
    1. Trenkwalder C, Kies B, Rudzinska M, Fine J, Nikl J, Honczarenko K, Dioszeghy P, Hill D, Anderson T, Myllyla V, Kassubek J, Steiger M, Zucconi M, Tolosa E, Poewe W, Surmann E, Whitesides J, Boroojerdi B, Chaudhuri KR, the RECOVER Study Group. Rotigotine effects on early morning motor function and sleep in Parkinson's disease: A double-blind, randomized, placebo-controlled study (RECOVER) Mov Disord. 2010.
    1. Babic T, Boothmann B, Polivka J, Rektor I, Boroojerdi B, H J. et al.Rotigotine transdermal patch enables rapid titration to effective doses in advanced-stage idiopathic Parkinson disease: subanalysis of a parallel group, open-label, dose-escalation study. Clin Neuropharmacol. 2006;29:238–242. doi: 10.1097/01.WNF.0000228179.83335.65.
    1. Jankovic J, Watts RL, Martin W, Boroojerdi B. Transdermal rotigotine: double-blind, placebo-controlled trial in Parkinson disease. Arch Neurol. 2007;64:676–682. doi: 10.1001/archneur.64.5.676.
    1. Barone P, Antonini A, Colosimo C, Marconi R, Morgante L, Avarello TP. et al.The PRIAMO study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease. Mov Disord. 2009;24:1641–1649. doi: 10.1002/mds.22643.
    1. Kim HJ, Park SY, Cho YJ, Hong KS, Cho JY, Seo SY. et al.Nonmotor symptoms in de novo Parkinson disease before and after dopaminergic treatment. J Neurol Sci. 2009;287:200–204. doi: 10.1016/j.jns.2009.07.026.
    1. Cheon SM, Ha MS, Park MJ, Kim JW. Nonmotor symptoms of Parkinson's disease: prevalence and awareness of patients and families. Parkinsonism Relat Disord. 2008;14:286–290. doi: 10.1016/j.parkreldis.2007.09.002.
    1. Wang G, Hong Z, Cheng Q, Xiao Q, Wang Y, Zhang J. et al.Validation of the Chinese Non-Motor Symptoms Scale for Parkinson's disease: Results from a Chinese pilot study. Clin Neurol Neurosurg. 2009;111:523–526. doi: 10.1016/j.clineuro.2009.02.005.
    1. Chaudhuri KR, Rudzinska M, Kies B. et al.Effect of Rotigotine on Non-Motor Symptom in subjects with Idiopathic Parkinson's Disease. Neurology. 2010;74(suppl.2):A299.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi